MarketPulse

brain tumor

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Delveinsight

Glioblastoma Market to Surge 13.2% Annually as Next-Gen Therapies Advance

Glioblastoma market valued at $900M to grow 13.2% annually through 2036, driven by next-generation immunotherapies and precision medicine approaching late-stage development.
MRKNVSRHHBYTLRYBAYRY+4clinical trialspersonalized medicine
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Adaptin Bio Gains OTCQB Listing as Glioblastoma Drug Enters Clinical Trials

Adaptin Bio ($APTN) approved for OTCQB quotation. Lead program APTN-101, a brain bispecific T cell engager for glioblastoma, receives FDA clearance for Phase 1 trials.
APTNPhase 1 clinical trialglioblastoma